Bicycle Therapeutics (BCYC)
(Delayed Data from NSDQ)
$27.02 USD
-0.22 (-0.81%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $27.01 -0.01 (-0.04%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth C Momentum F VGM
Income Statements
Fiscal Year end for Bicycle Therapeutics PLC Sponsored ADR falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 27 | 14 | 12 | 10 | 14 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 27 | 14 | 12 | 10 | 14 |
Selling & Adminstrative & Depr. & Amort Expenses | 217 | 131 | 77 | 62 | 40 |
Income After Depreciation & Amortization | -190 | -117 | -66 | -52 | -26 |
Non-Operating Income | 14 | 6 | 0 | 1 | -5 |
Interest Expense | 3 | 3 | 3 | 0 | 0 |
Pretax Income | -179 | -114 | -68 | -52 | -31 |
Income Taxes | 1 | -2 | -2 | -1 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -181 | -113 | -67 | -51 | -31 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -181 | -113 | -67 | -51 | -31 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -183 | -113 | -64 | -51 | -25 |
Depreciation & Amortization (Cash Flow) | 7 | 4 | 1 | 1 | 1 |
Income After Depreciation & Amortization | -190 | -117 | -66 | -52 | -26 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 35.59 | 29.66 | 25.06 | 19.15 | 11.05 |
Diluted EPS Before Non-Recurring Items | -5.08 | -3.80 | -2.67 | -2.66 | -2.77 |
Diluted Net EPS (GAAP) | -5.08 | -3.80 | -2.67 | -2.66 | -2.77 |
Fiscal Year end for Bicycle Therapeutics PLC Sponsored ADR falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 9.36 | 19.53 | 5.33 | 5.35 | 11.40 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 9.36 | 19.53 | 5.33 | 5.35 | 11.40 |
SG&A, R&D, and Dept/Amort Expenses | 56.01 | 51.24 | 59.57 | 56.15 | 54.51 |
Income After SG&A, R&D, and Dept/Amort Expenses | -46.65 | -31.71 | -54.24 | -50.80 | -43.11 |
Non-Operating Income | 7.77 | 5.62 | 6.28 | 3.99 | 0.81 |
Interest Expense | 0.82 | 0.82 | 0.82 | 0.81 | 0.82 |
Pretax Income | -39.70 | -26.91 | -48.78 | -47.63 | -43.12 |
Income Taxes | 0.12 | -0.35 | 0.32 | 2.27 | -0.52 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -39.81 | -26.56 | -49.10 | -49.90 | -42.60 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -39.81 | -26.56 | -49.10 | -49.90 | -42.60 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 51.99 | 42.56 | 42.42 | 39.58 | 30.19 |
Diluted EPS Before Non-Recurring Items | -0.77 | -0.62 | -1.16 | -1.26 | -1.41 |
Diluted Net EPS (GAAP) | -0.77 | -0.62 | -1.11 | -1.26 | -1.41 |